NCT00372983View on ClinicalTrials.gov

Safety and PK Study of NOV-205 to Treat Chronic HCV Who Fail Standard Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2006

Study Completion Date

December 31, 2007

Conditions
Hepatitis C
Interventions
DRUG

NOV-205

Sponsors
All Listed Sponsors
lead

Cellectar Biosciences, Inc.

INDUSTRY

NCT00372983 - Safety and PK Study of NOV-205 to Treat Chronic HCV Who Fail Standard Therapy | Biotech Hunter | Biotech Hunter